XGBoost improves classification of MGMT promoter methylation status in IDH1 wildtype glioblastoma

• Main Authors: Le, Nguyen Quoc Khanh, Do, Duyen Thi, Chiu, Fang-Ying, Yapp, Edward Kien Yee, Yeh, Hui-Yuan, Chen, Cheng-Yu
• Other Authors: School of Humanities
• Format: Article
• Language: English
• Published: 2021
• Subjects: Science::Medicine; Radiogenomics; Glioblastoma
• Online Access: https://hdl.handle.net/10356/145898
• Institution: Nanyang Technological University

Approximately 96% of patients with glioblastomas (GBM) have IDH1 wildtype GBMs, characterized by extremely poor prognosis, partly due to resistance to standard temozolomide treatment. O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a crucial prognostic biomarker for alky...